

Engerix™ B

1 - Trade name of medicinal product
Engerix™-B

2 - Qualitative and quantitative composition

Engerix™-B hepatitis B vaccine is a sterile suspension containing the purified major surface antigen of the virus manufactured by recombinant DNA technology, adsorbed onto aluminium hydroxide.
Engerix™-B is a genetically-engineered yeast cells (*Saccharomyces cerevisiae*) which carry the gene which codes for the major surface antigen of the hepatitis B virus (HBV). This hepatitis B surface antigen (HBsAg) expressed in yeast cells is purified by several physico-chemical steps. The HBsAg assembles spontaneously, in the absence of chemical treatment, into spherical particles of 20 nm in average diameter containing non-glycosylated HBsAg polyproteins and a lipid matrix consisting mainly of phospholipids. Extensive tests have demonstrated that these particles display the characteristic properties of natural HBsAg. The vaccine is highly purified, and exceeds the WHO requirements for recombinant hepatitis B vaccines. No substances of human origin are used in its manufacture.
A 20 µg dose vaccine (in 1.0 ml suspension) contains 20 µg HBsAg.
A 10 µg dose vaccine (in 0.5 ml suspension) contains 10 µg HBsAg.

3 - Pharmaceutical form
 Suspension for injection.

4 - Clinical particulars

4.1 Therapeutic indications

Engerix™-B is indicated for active immunisation against HBV infection caused by all known subtypes in subjects of all ages considered at risk of exposure to HBV. It can be expected that hepatitis D will also be prevented by immunisation with **Engerix™-B** as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.

Immunisation against hepatitis B is expected in the long term to reduce not only the incidence of this disease, but also its chronic complications such as chronic active hepatitis B and hepatitis B associated cirrhosis.

In areas of low prevalence of hepatitis B, immunisation is particularly recommended for those belonging to groups identified at risk of infection (see below), however, universal immunisation of all infants and adolescents will contribute to the control of hepatitis B on a population basis.

In areas of intermediate and high prevalence of hepatitis B, with most of the population at risk of acquiring the HBV, the best strategy is to provide universal immunisation of neonates, infants, children and adolescents, as well as adults belonging to groups at increased risk of infection.

The WHO, the US Immunisation Practices Advisory Committee (ACIP) and the American Academy of Paediatrics advocate that the vaccination of new-borns and/or the vaccination of adolescents is the optimal strategy for the control of hepatitis B in all countries.

Groups identified at increased risk of infection:

- Health Care Personnel.
- Patients frequently receiving blood products.
- Personnel and residents of institutions.
- Persons at increased risk due to their sexual behaviour.
- Illicit users of addictive injectable drugs.
- Travellers to areas with a high endemicity of HBV.
- Infants born of mothers who are HBV carriers.
- Persons originating from areas with a high endemicity of HBV.
- Patients with sickle-cell anaemia.
- Patients who are candidates for organ transplantation.
- Household contacts of any of the above groups and patients with acute or chronic HBV infection.
- Subjects with chronic liver disease (CLD) or at risk of developing CLD (e.g. Hepatitis C virus carriers, persons who abuse alcohol).
- Other: Police personnel, fire brigade personnel, armed forces personnel and anybody who through their work or personal lifestyle may be exposed to HBV.

4.2 Dosage and method of administration

Paedology
20 µg dose vaccine: The 20 µg dose (in 1.0 ml suspension) is intended for use in subjects 20 years of age and older.
10 µg dose vaccine: The 10 µg dose (in 0.5 ml suspension) is intended for use in neonates, infants and children up to and including the age of 19 years.
 However, the 20 µg vaccine can also be used in subjects from 11 years up to and including 15 years of age as a 2-dose schedule in situations when there is a low risk of hepatitis B infection during the vaccination period in compliance with the complete vaccination course as approved (see section 5.1 "Pharmacodynamic properties").

Primary immunisation schedule

- All subjects
- A 0, 1, 6 months schedule give optimal protection at month 7 and produces high antibody titres An accelerated schedule, with immunisation at 0, 1 and 2 months, will confer protection more quickly and is expected to provide better patient compliance. With this schedule, a fourth dose should be administered at 12 months as titres after the third dose are lower than those obtained after the 0, 1, 6 months schedule. In infants this schedule will allow for simultaneous administration of hepatitis B and other childhood vaccines.
- Subjects 20 years of age and above
- In exceptional circumstances, where an even more rapid induction of protection is required, e.g. persons travelling to areas of high endemicity and who commence a course of vaccination against hepatitis B within one month prior to departure, a schedule of three intramuscular injections given at 0, 7 and 21 days may be used. When this schedule is applied, a fourth dose is recommended 12 months after the first dose (see section 5.1 "Pharmacodynamic properties" for seroconversion rates).
- Subjects from 11 years up to and including 15 years of age
- The 20 µg vaccine may be administered in subjects from 11 years up to and including 15 years of age according to a 0, 6 months schedule. However, in this case, protection against hepatitis B infections may not be obtained until after the second dose (see section 5.1 "Pharmacodynamic properties"). Therefore, this schedule should be used only when there is a low risk of hepatitis B infection during the vaccination period. In subjects with a low risk of infection, a two-dose vaccination course can be assured. If both conditions can be assured (for instance patients undergoing haemodialysis, travellers to endemic regions and close contacts of infected subjects), the three-dose or the accelerated schedule of the 10 µg vaccine should be used.
- Patients with renal insufficiency including patients undergoing haemodialysis 16 years of age and above
- The primary immunisation schedule for patients undergoing haemodialysis is four double doses (2 x 20 µg) at elected date, 1 month, 2 months and 6 months from the date of the first dose. The immunisation schedule should be adapted in order to ensure that the anti-HBs antibody titre remains equal to or higher than the accepted protective level of 10 IU/L.
- Patients with renal insufficiency including patients undergoing haemodialysis up to and including 15 years of age, including neonates
- In circumstances where exposure to HBV has recently occurred (eg needlestick with contaminated needle) the first dose of **Engerix™-B** can be administered simultaneously with HBIG which however must be given at a separate injection site (see section 4.5 "Interactions with other medicinal products and other forms of interaction"). The 0, 1, 2-12 months immunisation schedule should be advised.
- Neonates born of mothers who are HBV carriers:

The immunisation with **Engerix™-B** (10 µg) of these neonates should start at birth, and one of the two immunisation schedules have to be followed. Either the 0, 1, 2 and 12 months or the 0, 1, 6 months schedule. In the latter schedule, a booster dose should be administered at 12 months. Based on adult experience, vaccination with a higher dosage of antigen may improve the immune response. Consideration should be given to serological testing following vaccination. Additional doses of vaccine may be needed to ensure a protective anti-HBs level \geq 10 IU/L.

4.3 Contra-indications

Engerix™-B should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous **Engerix™-B** administration.

4.4 Special warnings and special precautions for use

As with other vaccines, the administration of **Engerix™-B** should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection, however, is not a contraindication for immunisation. Because of the long incubation period of hepatitis B it is possible for unrecognised infection to be present at the time of immunisation. The vaccine may not prevent hepatitis B infection in such cases.

The vaccine will not prevent infection caused by other pathogens known to infect the liver such as hepatitis A, hepatitis C and hepatitis E virus. The immune response to hepatitis B vaccines is related to a number of factors, including older age, male gender, obesity, smoking habits and route of administration. In subjects who may respond less well to the administration of the hepatitis B vaccines (e.g. more than 40 years of age etc.), additional doses may be considered.

In patients with renal insufficiency including patients undergoing haemodialysis, HIV infected patients and persons with an impaired immune system, adequate anti-HBs antibody titres may not be obtained after the primary immunisation course and such patients may therefore require administration of additional doses of vaccine. (see section 4.2 "Paedology" – Patients with renal insufficiency including patients undergoing haemodialysis)

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of anaphylactic reactions following the administration of the vaccine. **Engerix™-B** should not be administered in patients with thrombocytopenia or bleeding disorders. **Engerix™-B** should not be administered intravenously. **Engerix™-B** should only be administered under no circumstances to be administered intravenously.

As with any vaccine, protective immune response may not be elicited in all vaccinees (see section 5.1 "Pharmacodynamic properties").

4.5 Interaction with other medicinal products and other forms of interaction
 The simultaneous administration of **Engerix™-B** and a standard dose of Hibig does not result in lower anti-HBs antibody titres provided that they are administered at separate injection sites. **Engerix™-B** can be given concomitantly with DTP, DT and/or polio vaccines. If this fits conveniently in an immunisation scheme recommended by the country Health Authority.

Engerix™-B can also be administered together with measles-mumps-rubella vaccines, Haemophilus influenzae b vaccine, hepatitis A vaccine and BCG. Different injectable vaccines should always be administered at different injection sites.

Engerix™-B may be used to complete a primary immunisation course started either with plasma-derived or with other genetically-engineered hepatitis B vaccines, or as a booster dose in subjects who have previously received a primary immunisation course with plasma-derived or with other genetically-engineered hepatitis B vaccines.

4.6 Pregnancy and Lactation

Pregnancy
 Adequate human data on use during pregnancy and adequate animal reproduction studies are not available. However, as with all inactivated viral vaccines one does not expect harm for the foetus. **Engerix™-B** should be used during pregnancy only when clearly needed, and the possible advantages outweigh the possible risks for the foetus.

Lactation

Adequate human data on use during lactation and adequate animal reproduction studies are not available. No contra-indication has been established.

4.7 Effects on ability to drive and use machines

The vaccine is unlikely to produce an effect on the ability to drive and use machines.

4.8 Undesirable effects

Engerix™-B is generally well tolerated. The following undesirable effects, usually mild and transient have been reported following the widespread use of the vaccine. As with other hepatitis B vaccines, in many instances, the causal relationship with the vaccine has not been established. Frequencies are reported as:

- Very common: (>1/10)
- Common: (>1/100, <1/10)
- Uncommon: (>1/1,000, <1/100)
- Rare: (>1/10,000, <1/1,000)
- Very rare: (<1/10,000) including isolated reports

General reactions: Common: redness, pain, swelling at injection site
Very rare: fainting, fever, fatigue, fever, malaise, influenza-like symptoms / **Very rare:** anaphylaxis, allergic reactions, including anaphylactoid reactions and mimicking severe sickness

Cardiovascular: **Very rare:** syncope, hypotension
Neurological and peripheral nervous system: Common: dizziness, headache, paraesthesia / **Very rare:** paralysis, neuropathy, neuritis (including Guillain-Barré syndrome, optic neuritis and multiple sclerosis), encephalitis, encephalopathy, meningitis, convulsions

Gastro-intestinal system: **Rare:** nausea, vomiting, diarrhoea, abdominal pain
Immunological disorder: **Very rare:** thrombocytopenia
Local and urinary system: **Rare:** abnormal liver function tests
Musculoskeletal system: **Rare:** arthralgia, myalgia / **Very rare:** arthritis
Respiratory systems: **Very rare:** bronchospasm like symptoms
Skin and appendages: **Rare:** rash, pruritus, urticaria / **Very rare:** angioedema, erythema multiforme
Vascular disorders: **Very rare:** vasculitis
White cell and red blood cell count system: **Very rare:** lymphadenopathy

In a comparative trial in subjects from 11 years up to and including 15 years of age, the incidence of local and general solicited symptoms reported after a two-dose regimen of **Engerix™-B** 20 µg was similar overall to that reported after the standard three-dose regimen of **Engerix™-B** 10 µg.

4.9 Overdose

Not applicable.

5 - Pharmacological properties

5.1 Pharmacodynamic properties
Engerix™-B induces specific humoral antibodies against HBsAg (anti-HBs antibodies). An anti-HBs antibody titre above 10 IU/L correlates with protection to HBV infection.

• Protective efficacy in risk groups
 In field studies, a protective efficacy between 95% and 100% was demonstrated in neonates, children and adults at risk.
 A 95% protective efficacy was demonstrated in neonates of HBsAg positive mothers, immunised according to the 0, 1 and 2 or 0, 1 and 6 schedules without the concomitant administration of Hibig at birth. However, simultaneous administration of HBsAg and vaccine at birth increase the protective efficacy to 98%.

• Seroconversion rate in healthy subjects
 When the 0, 1 and 6 months schedule is followed, > 96% of vaccinees have seroprotective levels of antibody 7 months after the first dose.
 When the 0, 1 and 2 months primary schedule plus a booster dose at month 12 is followed, 15% and 89% of vaccinees have seroprotective levels of antibody respectively one and three months after the first dose.

One month after the fourth dose 95.8% of vaccinees achieved seroprotective levels of antibody.
 For use in exceptional circumstances a two-dose immunisation schedule of 0, 7 and 21 day primary schedule plus a fourth at month 12 results in 65.2% and 76% of vaccinees having seroprotective levels of antibody within 1 and 5 weeks respectively following completion of the primary schedule. One month after the fourth dose 88.6% of vaccinees achieved seroprotective levels of antibody.

• Seroconversion rate in patients with renal insufficiency including patients undergoing haemodialysis: 16 years of age and above
 The primary immunisation (0, 1, 2 months) and booster doses (2, 6 months and 12 months) after the date of first dose results in 55.4 % and 87.1 % of vaccinees having seroprotective levels of antibody respectively 3 and 7 months after the first dose.

• Comparative table of the seroprotective rates (SP) obtained with the two different dosages and schedules licensed in subjects from 11 years up to and including 15 years of age:

Vaccine groups	Month 2 - SP (%)	Month 6 - SP (%)	Month 7 - SP (%)
Engerix™-B (10 µg (0, 1, 6 months schedule)	55.8	87.6	98.2
Engerix™-B (20 µg (0, 6 months schedule)	55.8	87.6	98.2

• Reduction in the incidence of hepatocellular carcinoma in children:
 A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6-14 years following a nationwide hepatitis B vaccination in Taiwan. There was a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

Appropriate safety tests have been performed.

6 - Pharmaceutical particulars

6.1 List of excipients
 Aluminium hydroxide, sodium chloride, sodium phosphate dihydrate, sodium dihydrogen phosphate, Polysorbate 20, water for injections. Multidose presentations contain 2-phenoxylethanol as preservative.

6.2 Incompatibilities

Engerix™-B should not be mixed with other vaccines.

6.3 Shelf life

The expiry date of the vaccine is indicated on the label and packaging.

6.4 Special precautions for storage

New and partially used vials should be stored at +2°C to +8°C. Partially used vials must be used the same day.
DO NOT FREEZE; discard if vaccine has been frozen.

Additional information on the stability

The following experimental data give indication of the stability of the vaccines and are not recommendations for storage (see under special precautions for storage). **Engerix™-B** has been kept at a refrigerator at +2°C to +8°C for 48 months without significant loss of potency.

Engerix™-B has been kept at 37°C for 3 months and 45°C for 1 week without loss of its immunogenicity in man.

6.5 Nature and contents of container

Engerix™-B is presented in a glass vial or glass prefilled syringe. The vials and prefilled syringes are made of neutral glass type 1, which conforms to European Pharmacopoeia Requirements. The content upon storage may present a fine white deposit with a clear colourless supernatant. Once shaken the vaccine is slightly opaque.

6.6 Instructions for use, handling and disposal (if necessary)
 The vaccine should be inspected visually for any foreign particulate matter and/or coloration prior to administration. Before use of **Engerix™-B**, the vaccine should be well shaken to obtain a slightly opaque, white suspension. Discard if the content appears otherwise.

When using a multidose vial, each syringe should be taken with a sterile needle and syringe. As with other vaccines, a dose of vaccine should be withdrawn under strict aseptic conditions and precautions taken to avoid contamination of the contents.

When using a vial, use different needles to pierce the rubber stopper and to inject the vaccine. For additional information please refer to the manufacturer.

Engerix™-B is a trademark.